@phdthesis{Schneider2022,
  author    = {Schneider, Alisa-Sophia Johanna Beatrice},
  title     = {Vergleich immunhistochemischer Markerprofile Her2/neu negativer, hormonrezeptorpositiver Mammakarzinome mit dem Recurrence-Score des OncotypeDX®},
  doi       = {10.25972/OPUS-27685},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-276858},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2022},
  abstract  = {Zur Entscheidungshilfe in der Therapiefindung des Mammakarzinoms haben sich bez{\"u}glich der Indikation zur Chemotherapie neben den klinischen und histopathologischen Kriterien in den letzten Jahren vorrangig Multigentests etabliert. In der vorliegenden Arbeit wurden Zusammenh{\"a}nge zwischen dem Oncotyp DX® und 18 immunhistochemischen Markern aus der Tumorbiologie f{\"u}r 78 F{\"a}lle hormonrezeptorpositiver, Her2/neu negativer Mammafr{\"u}hkarzinome mit niedrigem Lymphknotenstatus untersucht. Es erfolgten immunhistochemische F{\"a}rbungen an Microtissue-Arrays der Tumorproben. F{\"u}r die Marker AMACR, Cyclin D1, p53, MDM2 und PDL1 ergab sich eine klare statistisch signifikante Korrelation zum Recurrence-Score®des Oncotyp DX® und mit Einschr{\"a}nkungen auch f{\"u}r CDK4. Die Marker p27, Bcl2 und Glut 1 erreichten ein etwas niedrigeres Signifikanzniveau in der statistischen Analyse. Der immunhistochemische Routinemarker Ki67\% zeigte eine hochsignifikante Korrelation mit dem Recurrence-Score®. Hierdurch ergeben sich neue Perspektiven zur Risikostratifizierung des Mammakarzinoms, wie beispielsweise die konsekutive Entwicklung eines immunhistochemischen Scores mit pr{\"a}diktivem Wert f{\"u}r den Recurrence-Score® mit klinischer Anwendung als Pr{\"a}test oder als eigenst{\"a}ndiges Stratifizierungstool bei Brustkrebs.},
  subject      = {Oncotype DX®},
  language  = {de}
}
@article{JobsVontheinKoenigetal.2020,
  author    = {Jobs, Alexander and Vonthein, Reinhard and K{\"o}nig, Inke R. and Sch{\"a}fer, Jane and Nauck, Matthias and Haag, Svenja and Fichera, Carlo Federico and Stiermaier, Thomas and Ledwoch, Jakob and Schneider, Alisa and Valentova, Miroslava and von Haehling, Stephan and St{\"o}rk, Stefan and Westermann, Dirk and Lenz, Tobias and Arnold, Natalie and Edelmann, Frank and Seppelt, Philipp and Felix, Stephan and Lutz, Matthias and Hedwig, Felix and Borggrefe, Martin and Scherer, Clemens and Desch, Steffen and Thiele, Holger},
  title     = {Inferior vena cava ultrasound in acute decompensated heart failure: design rationale of the CAVA-ADHF-DZHK10 trial},
  series = {ESC Heart Failure},
  volume    = {7},
  journal   = {ESC Heart Failure},
  number    = {3},
  doi       = {10.1002/ehf2.12598},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-212692},
  pages     = {973 -- 983},
  year      = {2020},
  abstract  = {Aims Treating patients with acute decompensated heart failure (ADHF) presenting with volume overload is a common task. However, optimal guidance of decongesting therapy and treatment targets are not well defined. The inferior vena cava (IVC) diameter and its collapsibility can be used to estimate right atrial pressure, which is a measure of right-sided haemodynamic congestion. The CAVA-ADHF-DZHK10 trial is designed to test the hypothesis that ultrasound assessment of the IVC in addition to clinical assessment improves decongestion as compared with clinical assessment alone. Methods and results CAVA-ADHF-DZHK10 is a randomized, controlled, patient-blinded, multicentre, parallel-group trial randomly assigning 388 patients with ADHF to either decongesting therapy guided by ultrasound assessment of the IVC in addition to clinical assessment or clinical assessment alone. IVC ultrasound will be performed daily between baseline and hospital discharge in all patients. However, ultrasound results will only be reported to treating physicians in the intervention group. Treatment target is relief of congestion-related signs and symptoms in both groups with the additional goal to reduce the IVC diameter ≤21 mm and increase IVC collapsibility >50\% in the intervention group. The primary endpoint is change in N-terminal pro-brain natriuretic peptide from baseline to hospital discharge. Secondary endpoints evaluate feasibility, efficacy of decongestion on other scales, and the impact of the intervention on clinical endpoints. Conclusions CAVA-ADHF-DZHK10 will investigate whether IVC ultrasound supplementing clinical assessment improves decongestion in patients admitted for ADHF.},
  language  = {en}
}
@article{SchmittTatschVollhardtetal.2022,
  author    = {Schmitt, Andrea and Tatsch, Laura and Vollhardt, Alisa and Schneider-Axmann, Thomas and Raabe, Florian J. and Roell, Lukas and Heinsen, Helmut and Hof, Patrick R. and Falkai, Peter and Schmitz, Christoph},
  title     = {Decreased oligodendrocyte number in hippocampal subfield CA4 in schizophrenia: a replication study},
  series = {Cells},
  volume    = {11},
  journal   = {Cells},
  number    = {20},
  issn      = {2073-4409},
  doi       = {10.3390/cells11203242},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-290360},
  year      = {2022},
  abstract  = {Hippocampus-related cognitive deficits in working and verbal memory are frequent in schizophrenia, and hippocampal volume loss, particularly in the cornu ammonis (CA) subregions, was shown by magnetic resonance imaging studies. However, the underlying cellular alterations remain elusive. By using unbiased design-based stereology, we reported a reduction in oligodendrocyte number in CA4 in schizophrenia and of granular neurons in the dentate gyrus (DG). Here, we aimed to replicate these findings in an independent sample. We used a stereological approach to investigate the numbers and densities of neurons, oligodendrocytes, and astrocytes in CA4 and of granular neurons in the DG of left and right hemispheres in 11 brains from men with schizophrenia and 11 brains from age- and sex-matched healthy controls. In schizophrenia, a decreased number and density of oligodendrocytes was detected in the left and right CA4, whereas mean volumes of CA4 and the DG and the numbers and density of neurons, astrocytes, and granular neurons were not different in patients and controls, even after adjustment of variables because of positive correlations with postmortem interval and age. Our results replicate the previously described decrease in oligodendrocytes bilaterally in CA4 in schizophrenia and point to a deficit in oligodendrocyte maturation or a loss of mature oligodendrocytes. These changes result in impaired myelination and neuronal decoupling, both of which are linked to altered functional connectivity and subsequent cognitive dysfunction in schizophrenia.},
  language  = {en}
}